Summary & Overview
CPT 87913: SARS–CoV–2 Genotype Analysis by Next-Generation Sequencing
CPT code 87913 covers next-generation sequencing–based genotype analysis for patients with confirmed SARS–CoV–2 infection, identifying viral mutations that may affect transmissibility or disease severity. This capability supports public health surveillance, variant tracking, and clinical interpretation where variant information informs diagnostic and therapeutic considerations. Nationally, genomic surveillance remains a priority for pandemic response and ongoing monitoring of viral evolution.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, payer coverage scope, and the clinical context for use. The publication summarizes benchmark considerations for laboratory and facility reimbursement, highlights typical sites of service where CPT code 87913 is performed, and outlines the clinical rationale for genotype testing in confirmed SARS–CoV–2 cases.
This analysis is intended for a national audience and provides practical context on service type, sites of service, and the role of next-generation sequencing for SARS–CoV–2 genotype analysis. Data not available in the input: detailed payer policy specifics, associated taxonomies, ICD-10 mappings, related codes, and service-line billing details.
Billing Code Overview
CPT code 87913 describes genotype analysis of a specimen from a patient with confirmed severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2) infection. The test uses next-generation sequencing (NGS) to identify viral mutations that could affect transmissibility, virulence, or clinical management.
Service type: Molecular diagnostic sequencing / viral genomic sequencing
Typical site of service: Clinical laboratories, hospital laboratories, and reference sequencing centers
Clinical & Coding Specifications
Clinical Context
A patient with confirmed SARS–CoV–2 infection (positive RT-PCR) is admitted to an acute care hospital for progressive respiratory symptoms and concern for a new variant with increased transmissibility. A nasopharyngeal swab or lower respiratory specimen already collected for diagnostic testing is sent to the hospital molecular laboratory or a reference molecular pathology laboratory for genotype analysis using next‑generation sequencing. The clinical workflow: specimen accessioning and verification, nucleic acid extraction, library preparation, next‑generation sequencing targeted to the viral genome, bioinformatic variant calling and annotation, and a clinically focused report noting mutations of interest (for example, spike protein substitutions) that could affect transmissibility or disease severity. Results are communicated to the ordering infectious disease physician or hospital epidemiology team to inform infection control, public health reporting, and potential antiviral selection considerations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation/analysis component separate from the technical sequencing. |
TC |